The U.S. Food and Drug Administration (FDA) has granted fast track designation to the investigational therapy MNV-201 for the treatment of myelodysplastic syndrome (MDS), according to a news release from Minovia Therapeutics Ltd., a clinical-stage biotechnology company. Dr. Natalie Yivgi-Ohana, co-founder and CEO of Minovia, stated, “The fast track designation in MDS validates the urgency and potential of our mitochondrial-targeting therapy. “Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The FDA fast track designation may help bring this therapy to patients faster while allowing for closer collaboration between Minovia and regulators to address the urgent medical need. References“Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome,” by Minovia Therapeutics.